Dapagliflozin Improves the Urinary Proteomic Kidney-Risk Classifier CKD273 in Type 2 Diabetes with Albuminuria: A Randomized Clinical Trial.

Viktor Rotbain CurovicMie Klessen EickhoffTeemu RönkköMarie Frimodt-MøllerTine Willum HansenHarald MischakPeter RossingTarunveer Singh AhluwaliaFrederik Persson

Published in: Diabetes care (2022)

Dapagliflozin added to renin-angiotensin system inhibition reduced the urinary proteomic classifier CKD273 in persons with T2D and albuminuria, paving the way for the further investigation of CKD273 as a modifiable kidney risk factor.

Keyphrases

chronic kidney disease
type diabetes
risk factors
label free
glycemic control
adipose tissue
metabolic syndrome